solver.press

New testable hypothesis: "Zero-knowledge proofs of geospatial provenance assertions (e.g., 'this image was taken within 10km of a clinical trial site') can be integrated with federated transcriptomic datasets to enable privacy-preserving validation of spatial correlations between environmental exposures and MS-associated gene expression (e.g., CTSS pathway activity) without revealing raw loca

Computer ScienceAug 21, 2026Evaluation Score: 70%

New testable hypothesis: *"Zero-knowledge proofs of geospatial provenance assertions (e.g., 'this image was taken within 10km of a clinical trial site') can be integrated with federated transcriptomic datasets to enable privacy-preserving validation of spatial correlations between environmental exposures and MS-associated gene expression (e.g., CTSS pathway activity) without revealing raw loca

Adversarial Debate Score

65% survival rate under critique

Expert panel critique

Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.

Grok: {"code":"permission-denied","error":"Your team 66dc1710-5e0c-42e8-bdea-258e945fcd69 has either used all available credits or reached its monthly spending limit. To co...
ChatGPT: The hypothesis is technically plausible and falsifiable through an end-to-end prototype measuring privacy, proof soundness, and correlation validity, but the cited papers provide only adjacent support and the owner’s validated experiments are unrelated. Major unresolved issues include trustworthy...
Mistral: The hypothesis is falsifiable, novel, and well-aligned with validated experiments (e.g., privacy-preserving methods in federated datasets) and relevant literature (e.g., spatial transcriptomics, ZKPs for provenance). However, counterarguments exist—e.g., scalability of ZKPs for large geos...
Claude: The hypothesis is conceptually creative and technically plausible — ZKPs for geospatial provenance and federated transcriptomics are both active research areas — but it is severely underdeveloped as a testable scientific claim: the relevant papers address spatial transcriptomics tissue alignment ...

Supporting Research Papers

Computational Result

📖 Literature-assessed (LLM)· literature_meta

An LLM's reading of the literature — not computational verification.

Integration of zero-knowledge proofs with transcriptomic data is plausible but faces significant challenges.

Method: literature_meta · Result: inconclusive · Confidence: 60%

Formal Verification

Z3 logical consistency:✅ Consistent

Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.

Experimental Validation Package

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

A zero-knowledge proof (ZKP) protocol can attest that a biospecimen/metadata record originated within a bounded geographic region (e.g., "within 10km of clinical trial site X" or "within an EPA-defined pollution exposure zone") — verifiable by a third party with cryptographic soundness ≥99.99% (false-accept rate) and completeness ≥99% — while the verifier learns nothing about the exact coordinates beyond membership in the disclosed region (statistical distinguishability advantage <0.01 between true and simulated proof transcripts). Further, this ZKP-gated geolocation attribute can be joined with federated transcriptomic pipelines (e.g., CTSS/DNMT1/ZNF740 expression from GSE193770/GSE138614-style cohorts) such that a spatial correlation analysis (e.g., regional pollution index vs. CTSS log2FC) computed over ZKP-verified-but-location-hidden records produces effect estimates within 10% relative error of the same analysis computed with raw disclosed coordinates, on a synthetic/held-out ground-truth dataset.

Disproof criteria:
  1. Proof soundness failure: an adversarial prover can construct a valid ZKP for a false location claim with probability >10^-4 across 10,000 adversarial trials.
  2. Privacy leakage: a verifier or colluding third party can reconstruct the true coordinates (or narrow to <10km precision beyond the stated region) with >5% success rate above baseline guessing, measured via a distinguishing/membership-inference attack.
  3. Statistical distortion: the ZKP-gated correlation coefficient (region-hidden) deviates from the raw-coordinate correlation by >10% relative error, or changes significance at α=0.05 in >1/20 bootstrap resamples.
  4. Non-scalability: circuit compilation + proof generation exceeds 60 seconds per record on commodity hardware (16-core CPU, no GPU) at n=10,000 records, making federated deployment impractical.
  5. Biological null: if used as a downstream validation of CTSS, failure to detect the expected exposure-CTSS association in ANY analysis mode (raw or ZK-hidden) at effect size ≥ the GSE138614 replicated estimate (log2FC 0.673–1.16) constitutes disproof of the use-case (though not of the cryptographic method itself).

Spine & Adversarial ReadReady for validation

This hypothesis tests whether a zero-knowledge proof of geospatial region membership can replace raw coordinate disclosure in a federated transcriptomic analysis without changing the statistical conclusion of a spatial gene-expression correlation by more than 10%.

  • highThe biological substrate (CTSS/ZNF740/DNMT1 as MS targets) is entirely unreplicated internal analysis with no external peer review, and this EVP risks laundering cryptographic novelty by attaching it to unvalidated biology — the ZK method should be validated independently of any specific gene-expression claim.
    Partially addressed: the protocol explicitly separates cryptographic/statistical validation (synthetic data, steps 1-9) from any biological claim, and DEPENDENCIES lists CTSS/DNMT1/ZNF740 replication as prerequisites for the real-pilot phase only. However, the EVP does not fully resolve why CTSS specifically (vs. any other spatially-varying biomarker) was chosen as the motivating example beyond narrative convenience — this should be reframed as method-first with CTSS as one of several possible test cases.
  • highWhy zero-knowledge proofs specifically, rather than simpler, cheaper privacy techniques (differential privacy on coordinates, k-anonymity spatial cloaking, secure multi-party computation, or trusted execution environments) that are already well-established in federated health data literature? The methodology justification for ZKPs over these alternatives is not stated.
    Gap acknowledged, not resolved. ZKPs offer a unique property (cryptographic soundness of a *provenance claim* — proving the location predicate is true — rather than merely obscuring it), which DP/k-anonymity do not provide since they don't verify the claim's truthfulness. This distinction (verification vs. obfuscation) should be made an explicit comparison arm in the protocol (Step 3.5, not currently included): benchmark ZKP against DP-noised coordinates and secure-aggregation MPC on the same synthetic dataset to demonstrate the utility/privacy/verifiability tradeoff empirically rather than asserting ZKP superiority a priori.
  • mediumThe statistical fidelity target (relative error <10%) is compared only against a synthetic ground truth with a single injected effect size (r=0.3); real MS-exposure correlations may be much weaker (CTSS log2FC 0.67-1.16 is a modest expression effect, not necessarily reflecting a strong spatial exposure correlation), making the region-binning privacy tradeoff potentially unworkable at real effect sizes.
    Not resolved — the protocol should add a power-analysis sub-study varying injected effect size (r = 0.1 to 0.5) and region granularity to map the actual usable operating range before claiming general success, since a single r=0.3 synthetic benchmark is insufficiently conservative for a modest real-world effect.

Experimental Protocol

Minimum Viable Test (MVT): A two-arm synthetic-data benchmark.

  • Arm A (ground truth): Simulate N=5,000 synthetic patient records with (lat/lon, simulated CTSS expression value drawn from a model calibrated to GSE138614 effect sizes + spatial exposure gradient with known ground-truth correlation r=0.3).
  • Arm B (ZK-gated): Same records, but location replaced by a ZKP attestation of "within region R_i" for 20 predefined regions; raw coordinates withheld from the analysis engine.
  • Compute Pearson/Spearman correlation and mixed-effects regression (CTSS ~ exposure_proxy + region_random_effect) in both arms; compare coefficients, CIs, and p-values.
  • Separately run cryptographic benchmarks: proof generation time, verification time, proof size, soundness/completeness under fuzzing (10,000 malicious proof attempts with off-region coordinates).
Required datasets:
  • Synthetic geospatial-transcriptomic cohort (generated in-house, N=5,000–20,000 simulated patients) calibrated on GSE138614 CTSS effect sizes (log2FC 0.673–1.16) and public environmental exposure layers (EPA AQS air quality data, satellite-derived pollution indices).
  • GSE193770, GSE108000, GSE138614 (real transcriptomic data, for effect-size calibration only — these datasets do NOT contain real patient geolocation and cannot be used for the spatial-privacy test directly; a synthetic geo-layer must be grafted on).
  • A ZKP framework/toolkit: circom + snarkjs (Groth16), or Halo2 (no trusted setup), or gnark (Go, fast prover).
  • Federated learning/analytics simulation environment: Flower, PySyft, or custom MPI-based federation across ≥3 simulated "sites."
  • GTEx v10 (for any tissue-expression cross-referencing of CTSS, ancillary only).
Success:
  • Soundness: false-accept rate <10^-4 over 10,000 adversarial trials.
  • Privacy: membership-inference/reconstruction AUC ≤0.55 (near-chance) against the ZK-gated pipeline.
  • Statistical fidelity: relative error between Arm A and Arm B correlation/regression coefficients <10%; p-value significance calls concordant in ≥95% of bootstrap resamples.
  • Performance: proof generation <5s/record, verification <100ms/record, total pipeline overhead <2x the raw-coordinate pipeline at N=10,000.
  • Federation robustness: results stable (coefficient drift <15%) across 3–5 simulated heterogeneous sites with dropout up to 20%.
Failure:
  • Any soundness failure rate >10^-3 in adversarial testing → cryptographic disproof.
  • Reconstruction AUC >0.65 → privacy disproof.
  • Relative statistical error >20% or discordant significance calls in >10% of resamples → statistical-utility disproof.
  • Proof generation time >60s/record at N=10,000 (impractical for registry-scale deployment) → scalability disproof.
  • Real-pilot (step 10) shows CTSS-exposure association direction reversal or non-replication vs. site-internal raw analysis → use-case disproof (biological, not cryptographic).

ROI Projection

Commercial:
  • Direct: licensable privacy-infrastructure IP (ZK circuit library for geospatial health-data predicates) applicable beyond MS to any exposure-disease research (cancer clusters, environmental toxicology, infectious disease).
  • Platform value: could underpin a federated-research-as-a-service product for pharma/CRO multi-site trials requiring geographic eligibility verification (e.g., "within 10km of trial site") without PHI exposure — addressable market includes clinical trial recruitment compliance tooling (est. $50–150M niche market).
  • Regulatory value: potential fast-track alignment with GDPR/HIPAA "privacy by design" mandates, reducing legal/compliance overhead for multi-national MS consortia (e.g., MSBase, iConquerMS).
  • Biological upside (contingent, not validated here): if CTSS/DNMT1/ZNF740 targets independently validate, this infrastructure directly accelerates their clinical biomarker/trial-site epidemiology studies.

TIME_TO_RESULT_DAYS: 60 (For the minimum viable synthetic-only cryptographic + statistical fidelity benchmark. Full validation including real-site pilot and audit: ~365 days.)

Implementation Sketch

# --- Circuit definition (circom-like pseudocode) ---
template RegionMembership() {
    signal input lat;         // private
    signal input lon;         // private
    signal input region_id;   // public
    signal input region_center_lat; // public
    signal input region_center_lon; // public
    signal input radius_km;         // public
    signal output valid;

    dist <== haversine(lat, lon, region_center_lat, region_center_lon);
    valid <== LessThan(dist, radius_km);
}

# --- Client side (per patient) ---
def generate_proof(true_lat, true_lon, region):
    witness = {lat: true_lat, lon: true_lon, region_id: region.id, ...}
    proof = snark_prove(circuit=RegionMembership, witness=witness)
    return proof, region.id  # coordinates never leave client

# --- Federated aggregation server ---
def ingest_record(proof, region_id, ctss_value, covariates):
    assert snark_verify(proof, public_inputs=region_id)
    db.insert(region_id, ctss_value, covariates)  # no raw coords stored

def run_analysis():
    df = db.fetch_all()  # only region_id + expression + covariates
    model = mixedlm("ctss_value ~ exposure_index(region_id) + covariates",
                     groups=df.region_id)
    return model.fit()

# --- Adversarial fuzz harness ---
for trial in range(10000):
    fake_coords = perturb_outside_region(true_coords, region)
    proof = attempt_forge_proof(fake_coords, region)
    assert not snark_verify(proof)  # must fail

# --- Privacy attack harness ---
train_membership_inference_classifier(proof_transcripts, auxiliary_metadata)
measure_AUC_vs_baseline()
Abort checkpoints:
  1. After circuit design (Day 10): if constraint count exceeds 10^6 or proving time exceeds 30s/record in initial benchmark → abort/redesign before full-scale build.
  2. After adversarial fuzzing (Day 25): if soundness failure rate >10^-3 → abort, do not proceed to statistical fidelity testing.
  3. After privacy attack simulation (Day 35): if reconstruction AUC >0.65 → abort, protocol fundamentally leaky.
  4. After statistical fidelity comparison (Day 45): if relative error >20% → abort real-pilot planning, redesign region-binning strategy.
  5. Before real-site IRB pilot (Day 60): require independent cryptographic audit sign-off; if audit identifies critical vulnerability → abort real-data phase indefinitely.

NAMED_EXPERTS: []

CLOSEST_EXISTING_WORK: []

NOVELTY_NARROWING_REQUIRED: false

Source

AegisMind Research
Need AI to work rigorously on your problems? AegisMind uses the same multi-model engine for personal and professional use. Get started